June 10, 2016Open Access

A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

BEZ235 twice daily resulted in significant toxicity without objective responses; further development of this compound will not be pursued in this disease.

Leer artículo completoexternamente

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Carlo et al. (Fri,) studied this question.

synapsesocial.com/papers/69d7457f8e958094d1b8aa58 https://doi.org/https://doi.org/10.1634/theoncologist.2016-0145

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Doubling Down on mTOR Inhibition: Harnessing ZEBRA for Insights2015 · 5 citations
2Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex2005 · 6,178 citations
3A randomized phase II study of GDC-0980 versus everolimus in metastatic renal cell carcinoma (mRCC) patients (pts) after VEGF-targeted therapy (VEGF-TT).2014 · 19 citations
4A dose-escalation study with the novel formulation of the oral pan-class I PI3K inhibitor BEZ235, solid dispersion system (SDS) sachet, in patients with advanced solid tumors.2011 · 46 citations
5A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine Tumours.2016 · 86 citations

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo